FONDO-LOW

Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 Mg Versus 5 Mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: the FONDO-LOW Study

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
172 patients (estimated)
Sponsors
Augusta University Medical Center
Tags
Antipsychotic, Pre-Autologous Stem Cell Transplant, Randomization
Trial Type
Supportive
Last Update
1 month ago
SparkCures ID
1994
NCT Identifier
NCT06588413

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.